Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage

A subarachnoid space and composition technology, which can be used in drug combinations, active ingredients of heterocyclic compounds, blood diseases, etc., can solve problems such as expensive, time-consuming, and hindering systemic doses.

Inactive Publication Date: 2017-09-01
EDGE THERAPEUTICS
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the treatments described above are expensive, time-consuming, and only partially effective
[0145] Physicians have been working for more than 35 years to prevent or reduce the incidence of adverse consequences of SAH, including vasospasm, with limited success due to side effects or lack of effectiveness of currently available drugs
Without being bound by theory, it is believed that systemic delivery of voltage-gated calcium channel blockers may result in side effects that counteract the beneficial effects on vasospasm, such as systemic hypotension and pulmonary vasodilation with pulmonary edema, which hinder higher systemic dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
  • Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
  • Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0481] Example 1. Pilot Study 1 - Effect of Nimodipine Formulation on Cerebral Vasospasm in Canine Model of Subarachnoid Hemorrhage (SAH)

[0482] Materials and Methods

[0483] preparation

[0484] A test formulation of a microparticulate nimodipine formulation with uniform particle size distribution was prepared by combining a polymer solution (eg, a 50-50 glycolide-lactide blend) with a solvent in the presence of nimodipine. The mixture is added to a surfactant-containing aqueous solution to form an emulsion, and the solvent is separated off to produce a flowable microparticle nimodipine formulation. The initial drug loading was 65%, ie, 65% nimodipine and 35% polymer. The average particle size is about 52μ.

[0485] The microparticulate nimodipine formulation is combined with a pharmaceutical carrier to form the pharmaceutical composition of the present invention. When the device for delivery is a surgical injection device and the site of delivery is a cerebral artery ...

Embodiment 2

[0539] Example 2. Study 2 - Effect of nimodipine formulations on cerebral vasospasm in a canine model of subarachnoid hemorrhage (SAH)

[0540] Materials and Methods

[0541] preparation

[0542] A test formulation comprising a microparticulate nimodipine formulation with a uniform particle size distribution was prepared by combining a polymer solution (eg, a 50-50 glycolide-lactide blend) with a solvent in the presence of nimodipine. The mixture is added to a surfactant-containing aqueous solution to form an emulsion, and the solvent is separated off to produce a flowable microparticle nimodipine formulation. The initial drug loading was 65%, ie, 65% nimodipine and 35% polymer. The average particle size is about 52μ.

[0543] The microparticulate nimodipine formulation is combined with a pharmaceutical carrier to form the pharmaceutical composition of the present invention. When the device used for delivery is a surgical injection device and the site of delivery is in clo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
sizeaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The described invention provides a pharmaceutical composition, delivery system and a method for treating a delayed complication associated with a brain injury in a mammal and improving its prognosis in a mammal by implanting a therapeutically effective amount of the pharmaceutical composition containing a voltage-gated calcium channel blocker and a pharmaceutically acceptable carrier into a predetermined location in the brain, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Description

[0001] This application is a divisional application of the following applications: filing date: February 13, 2012; application number: 201280013759.2 (PCT / US2012 / 024893); invention title: same as above. [0002] Cross References to Related Applications [0003] This application claims priority to U.S. Provisional Application No. 61 / 441,695, filed February 11, 2011, and is a continuation-in-part of U.S. Application No. 12 / 137,320, filed June 11, 2008, which claimed 2007 Priority to U.S. Provisional Application No. 60 / 976,902, filed October 29, 2007, and U.S. Provisional Application No. 60 / 943,124, filed June 11, 2007. Each of these applications is incorporated herein by reference in its entirety. technical field [0004] The present invention relates to compositions, systems and methods for treating adverse consequences of subarachnoid hemorrhage. Background technique [0005] The human brain accounts for only about 2% of the total body weight, yet it receives about 15% of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K9/16A61K47/34A61K31/4422A61P9/10A61P7/02A61P25/00
CPCA61K9/0019A61K9/0085A61K9/06A61K9/1647A61K9/1652A61K31/4422A61P25/00A61P25/28A61P29/00A61P3/00A61P3/14A61P35/00A61P7/00A61P7/02A61P7/04A61P9/00A61P9/08A61P9/10A61K31/44A61K9/16A61M5/158A61M25/01
Inventor 布赖恩.A.洛伊特纳骆克.R.麦克唐纳
Owner EDGE THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com